Yung Zip Chemical, a leading active pharmaceutical ingredient (API) manufacturer, saw its core business profits double in the first half of 2024, with earnings per share (EPS) reaching NT$1.34, marking a historic high for the same period. Looking ahead to the second half of the year, despite a slowdown in contract manufacturing orders, the company anticipates continued growth driven by its API products and an influx of orders from its parent company, Yung Shin Pharmaceutical, starting from September and October. It is projected that the company’s revenue will grow by more than 20% for the full year, with EPS expected to hit NT$2.5, setting a new record.
Read more
